Cargando…

Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis

Biomarkers predicting fingolimod (FTY) treatment response in relapsing-remitting multiple sclerosis (RRMS) are lacking. Here, we performed extensive functional immunophenotyping using multiparametric flow cytometry to examine peripheral immune changes under FTY treatment and explore biomarkers of FT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghadiri, Mahtab, Rezk, Ayman, Li, Rui, Evans, Ashley, Giacomini, Paul S., Barnett, Michael H., Antel, Jack, Bar-Or, Amit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962338/ https://www.ncbi.nlm.nih.gov/pubmed/31941953 http://dx.doi.org/10.1038/s41598-019-57114-2

Ejemplares similares

Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
por: Ghadiri, Mahtab, et al.
Publicado: (2017)

Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study
por: Mao-Draayer, Yang, et al.
Publicado: (2022)

Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets
por: Hjorth, Maria, et al.
Publicado: (2020)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod
por: Cohen, Jeffrey A, et al.
Publicado: (2019)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023)

Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review
por: Ghadiri, Fereshteh, et al.
Publicado: (2023)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
por: Marriott, James J.
Publicado: (2011)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
por: Bascuñana, Pablo, et al.
Publicado: (2020)

Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2017)

Sequencing the immunopathologic heterogeneity in multiple sclerosis
por: Antel, Jack P, et al.
Publicado: (2015)

Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)

Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis
por: Petsas, Nikolaos, et al.
Publicado: (2019)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients – preliminary study
por: Rudnicka, Julia, et al.
Publicado: (2015)

Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis
por: Li, Rui, et al.
Publicado: (2016)

Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis
por: Portaccio, Emilio
Publicado: (2011)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015)

Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report
por: Ueda, Naoko, et al.
Publicado: (2015)

Cardiac repolarization during fingolimod treatment in patients with relapsing–remitting multiple sclerosis
por: Laiho, Aapo, et al.
Publicado: (2018)

Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis
por: Sato, Kazunori, et al.
Publicado: (2018)

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
por: Vollmer, Brandi, et al.
Publicado: (2017)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results
por: Cohen, Jeffrey A., et al.
Publicado: (2019)

Mild COVID-19 symptoms in a patient with multiple sclerosis in uninterrupted treatment with fingolimod
por: Medeiros da Silva, Marina, et al.
Publicado: (2022)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Lymphocytes subset composition and modulation of sphingosie-1-phosphate mediated migration in multiple sclerosis patients treated with fingolimod or interferon-β
por: Sic, Heiko, et al.
Publicado: (2012)

Erratum: microRNA dysregulation in multiple sclerosis
por: Moore, Craig S., et al.
Publicado: (2013)

A Case of Posterior Reversible Encephalopathy Syndrome Associated with Gilenya(®) (Fingolimod) Treatment for Multiple Sclerosis
por: Lindå, Hans, et al.
Publicado: (2015)

Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis
por: Ferret-Sena, Véronique, et al.
Publicado: (2022)

Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure
por: Malhotra, Sunny, et al.
Publicado: (2023)

MicroRNA dysregulation in multiple sclerosis
por: Jr, Omar de Faria, et al.
Publicado: (2013)

Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial
por: Cree, Bruce A. C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i2tihf6qf8re6k5ojef0agvqkv